A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) (ATTITUD)
Primary Purpose
Urticaria, Chronic Idiopathic Urticaria
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
desloratadine
desloratadine
Sponsored by
About this trial
This is an interventional treatment trial for Urticaria
Eligibility Criteria
Inclusion Criteria:
- Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subjects must be >= 18 years of age
- Women of childbearing potential must have a negative urine pregnancy test at Visit 1 (Day 1) and must be using an acceptable method of birth control during the study.
- Subjects must be in general good health; ie, they must be free of any clinically significant disease (other than CIU) that would interfere with study evaluations.
- Subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary.
- Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1.
Exclusion Criteria:
- Women who are pregnant or nursing.
- Subjects who used any investigational drug in the last 30 days prior to Visit 1
- Subjects with asthma requiring chronic use of inhaled or systemic corticosteroids.
- Subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to Baseline.
- Subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to Baseline.
- Subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism.
- Subjects treated by immunosuppressive drugs.
- Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1.
- Subjects with a history of hypersensitivity to desloratadine or any of its excipients.
- Subjects previously randomized into this study.
- Subjects who have any clinically significant metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety.
- Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
- Subjects with a history of noncompliance with medications or treatment protocols.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Continuous Treatment
PRN regimen
Arm Description
Outcomes
Primary Outcome Measures
Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.
Secondary Outcome Measures
Estimation of disease free period after 3 months of daily treatment.
Average usage of rescue medication
Change from Visit 2 in pruritus symptom score assessed by the patient.
% of patients free of symptoms 2 months after Visit 4
Changes from Visit 2 of overall conditions of CIU
Discontinuation due to treatment failure
Investigator's assessment of response to therapy
Quality of disease control
Average consumption of treatment between Visit 2 and Visit 5
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00783354
Brief Title
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
Acronym
ATTITUD
Official Title
A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
April 1, 2003 (Actual)
Primary Completion Date
February 1, 2004 (Actual)
Study Completion Date
April 1, 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Organon and Co
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (CIU) patients, after an initial 4-weeks of daily treatment: prolonging systematic daily treatment or as needed (PRN; in the case of symptoms).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urticaria, Chronic Idiopathic Urticaria
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
129 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Continuous Treatment
Arm Type
Active Comparator
Arm Title
PRN regimen
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
desloratadine
Other Intervention Name(s)
Aerius, SCH 34117
Intervention Description
Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (Placebo) in case of symptoms for 2 months.
Intervention Type
Drug
Intervention Name(s)
desloratadine
Other Intervention Name(s)
Aerius, SCH 34117
Intervention Description
Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (desloratadine 5 mg) in case of symptoms for 2 months.
Primary Outcome Measure Information:
Title
Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Estimation of disease free period after 3 months of daily treatment.
Time Frame
2 months
Title
Average usage of rescue medication
Time Frame
2 months
Title
Change from Visit 2 in pruritus symptom score assessed by the patient.
Time Frame
2 months
Title
% of patients free of symptoms 2 months after Visit 4
Time Frame
2 months
Title
Changes from Visit 2 of overall conditions of CIU
Time Frame
2 months
Title
Discontinuation due to treatment failure
Time Frame
2 months
Title
Investigator's assessment of response to therapy
Time Frame
2 months
Title
Quality of disease control
Time Frame
2 months
Title
Average consumption of treatment between Visit 2 and Visit 5
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
Subjects must be >= 18 years of age
Women of childbearing potential must have a negative urine pregnancy test at Visit 1 (Day 1) and must be using an acceptable method of birth control during the study.
Subjects must be in general good health; ie, they must be free of any clinically significant disease (other than CIU) that would interfere with study evaluations.
Subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary.
Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1.
Exclusion Criteria:
Women who are pregnant or nursing.
Subjects who used any investigational drug in the last 30 days prior to Visit 1
Subjects with asthma requiring chronic use of inhaled or systemic corticosteroids.
Subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to Baseline.
Subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to Baseline.
Subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism.
Subjects treated by immunosuppressive drugs.
Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1.
Subjects with a history of hypersensitivity to desloratadine or any of its excipients.
Subjects previously randomized into this study.
Subjects who have any clinically significant metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety.
Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
Subjects with a history of noncompliance with medications or treatment protocols.
12. IPD Sharing Statement
Citations:
PubMed Identifier
19133920
Citation
Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009 Apr;64(4):605-12. doi: 10.1111/j.1398-9995.2008.01913.x. Epub 2008 Dec 30.
Results Reference
result
Available IPD and Supporting Information:
Available IPD/Information Type
CSR Synopsis
Available IPD/Information URL
http://www.merck.com/clinical-trials/policies-perspectives.html
Learn more about this trial
A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
We'll reach out to this number within 24 hrs